VIVUS (VVUS) Stock Price, News & Analysis

Company Overview

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.26 to $0.47
• 52-Week Range: N/A
• Volume: 2.03 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $7.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VVUS Stock Analysis - Frequently Asked Questions

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter.

When did VIVUS's stock split?

VIVUS's stock reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Novavax (NVAX), CymaBay Therapeutics (CBAY) and Amarin (AMRN).

Company Calendar

• Last Earnings: 5/06/2020
• Today: 1/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VVUS
• CUSIP: 92855110
• CIK: 881524
• Web: www.vivus.com
• Phone: (650) 934-5200
• Fax: N/A
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-31,500,000.00
• Net Margins: -39.28%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -12.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.28

Sales & Book Value

• Annual Sales: $69.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.50) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,867,000
• Free Float: N/A
• Market Cap: $7.33 million
• Optionable: Optionable
• Beta: -0.84